Immunotherapy and chemoradiation before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma at the gastroesophageal junction (where the stomach meets the esophagus) that is stage III and can be surgically removed.
- You are between 18 and 75 years old.
- You have not had any previous cancer treatment for this disease, such as chemotherapy, radiation, or surgery.
- Your overall health is reasonably good, with a performance status of 0 to 2 (able to care for yourself).
- Your heart, liver, kidney, and blood cell counts are within acceptable limits as shown by lab tests.
- If you are able to have children, you agree to use effective contraception during and for a period after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.